Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Gross Profit (2016 - 2025)

Guided Therapeutics (GTHP) has disclosed Gross Profit for 16 consecutive years, with $458000.0 as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 23000.0% to $458000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $572000.0 through Dec 2025, up 28500.0% year-over-year, with the annual reading at $571000.0 for FY2025, 28450.0% up from the prior year.
  • Gross Profit hit $458000.0 in Q4 2025 for Guided Therapeutics, up from $35000.0 in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $458000.0 in Q4 2025 to a low of -$79000.0 in Q4 2022.
  • Historically, Gross Profit has averaged $35125.0 across 5 years, with a median of $4000.0 in 2022.
  • Biggest five-year swings in Gross Profit: plummeted 292.68% in 2022 and later surged 23000.0% in 2025.
  • Year by year, Gross Profit stood at $41000.0 in 2021, then tumbled by 292.68% to -$79000.0 in 2022, then surged by 120.25% to $16000.0 in 2023, then tumbled by 112.5% to -$2000.0 in 2024, then soared by 23000.0% to $458000.0 in 2025.
  • Business Quant data shows Gross Profit for GTHP at $458000.0 in Q4 2025, $35000.0 in Q3 2025, and $79000.0 in Q2 2025.